Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28835527 | 0.91 | — | — | |
| SCHEMBL24254052 | 0.89 | — | — | |
| SCHEMBL503209 | 0.89 | — | — | |
| SCHEMBL8192003 | 0.86 | SMN1; SMN2 (0.35) | — | |
| SCHEMBL28882571 | 0.86 | SMN1; SMN2 (0.35) | — | |
| SCHEMBL16878573 | 0.84 | SLC6A1 (0.38) | — | |
| SCHEMBL702038 | 0.83 | — | — | |
| SCHEMBL23505391 | 0.83 | — | — | |
| SCHEMBL16878175 | 0.78 | — | — | |
| SCHEMBL1449497 | 0.77 | CCR5 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030176416-A1 | Aryl and heteroaryl diazabicycloalkanes, their preparation and use | NEUROSEARCH A/S (DK) | 2003-09-18 | — | — | US | claimed |
| EP-1301514-A1 | ARYL AND HETEROARYL DIAZABICYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2003-04-16 | — | — | EP | claimed |
| WO-2002002564-A1 | ARYL AND HETEROARYL DIAZABICYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2002-01-10 | — | — | WO | claimed |
| WO-2013057205-A1 | DIAZABICYCLO- AND DIAZASPIRO-ALKANE DERIVATIVES AS PHOSPHODIESTERASE-5 INHIBITORS | TECHNISCHE UNIVERSITAET WIEN (AT) | 2013-04-25 | — | — | WO | disclosed |
| US-8399457-B2 | Pharmaceutical compounds | NEUROSCIENZE PHARMANESS S.C. A.R.L. (IT) | 2013-03-19 | — | — | US | disclosed |
| US-20100029622-A1 | MICROEMULSIONS | NEUROSCIENZE PHARMANESS S.C.A.R.L. (IT) | 2010-02-04 | — | — | US | disclosed |
| US-20100028257-A1 | PHARMACEUTICAL COMPOUNDS | NEUROSCIENZE PHARMANESS S.C. A.R.L. (IT) | 2010-02-04 | — | — | US | disclosed |
| US-7060699-B2 | Aryl and heteroaryl diazabicycloalkanes, their preparation and use | NEUROSEARCH A/S (DK) | 2006-06-13 | — | — | US | disclosed |
| US-20030176416-A1 | Aryl and heteroaryl diazabicycloalkanes, their preparation and use | NEUROSEARCH A/S (DK) | 2003-09-18 | — | — | US | disclosed |
| EP-1301514-A1 | ARYL AND HETEROARYL DIAZABICYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2003-04-16 | — | — | EP | disclosed |
| WO-2002002564-A1 | ARYL AND HETEROARYL DIAZABICYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100028257-A1 | PHARMACEUTICAL COMPOUNDS | OPRD1, OPRK1, OPRM1 | HTR3A 179/4885 |
| US-20030176416-A1 | Aryl and heteroaryl diazabicycloalkanes, their preparation and use | CHRNA7, CHRNA5, CHRNA2 | HTR3A 59/4885 |
| US-20100029622-A1 | MICROEMULSIONS | LIPA, APOB, LIPC | HTR3A 1235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.